Clinical Trial

EXOMIND (BTL-699-2) for the Improvement of Sleep Quality and Reduction of Stress

Completed
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate whether the treatment with BTL-699-2 device is able to improve sleep quality and reduce stress in adults above the age of 22 years. The main questions it aims to answer are: Does the treatment with BTL-699-2 device improve sleep quality? Does the treatment with BTL-699-2 device reduce stress? Participants will be asked to: * Undergo six treatments * Complete the Pittsburgh Sleep Quality Index * Complete the Perceived Stress Scale Questionnaire * Complete the Sleep and Stress Assessment Questionnaire * Complete the Therapy Comfort and Subject Satisfaction Questionnaire
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-06-11; most recent amendment 2026-03-25.
Status change: Recruiting → Completed 2026-03-25
Trial Details
NCT Number NCT07027657
Lead Sponsor BTL Industries Ltd.
Conditions Sleep Quality, Stress Reduction
Enrollment 43 participants
Start Date 2025-05-02
Primary Completion 2025-11-11 (estimated)
Study Completion 2025-11-11 (estimated)
Updated on ClinicalTrials.gov 2026-03-30